百利天恒注射用iza-bren用于局部晚期或转移性尿路上皮癌患者纳入突破性治疗品种名单

Core Viewpoint - The company, Bai Li Tian Heng, announced that its self-developed drug, iza-bren, has been included in the list of breakthrough therapies by the National Medical Products Administration for treating advanced or metastatic urothelial carcinoma patients who have failed previous platinum-based chemotherapy and PD-1/PD-L1 inhibitors [1] Group 1: Drug Development - Iza-bren is a first-in-class, new concept, and the only drug currently in Phase III clinical trials for its indication [1] - The drug has received breakthrough therapy designation for one indication from the U.S. Food and Drug Administration [1] Group 2: Regulatory Milestones - As of now, iza-bren has seven indications included in the breakthrough therapy list by the drug review center [1]